
PRP, low-level laser therapy, and FDA-approved topical and oral treatments. Hair loss affects over 80 million Americans, and most markets have zero dedicated regenerative hair clinics to serve them.
Book a Strategy CallHair loss affects roughly 80 million Americans, men and women, and the vast majority of those individuals have never had access to a regenerative treatment clinic in their local market. Most dermatologists don't offer clinical-grade PRP or restoration protocols. Most salons can't provide clinical-grade treatment. The gap between demand and available clinical supply is one of the widest in the cash-pay health space.
The hair regeneration category is growing faster than provider supply. Patients are already searching, and the market research ACG conducts before every engagement shows strong local search volume for hair loss treatment in virtually every mid-size and major U.S. market. The question is who opens the clinic first.
Hair regeneration works as a standalone model and as a powerful complement to any longevity, hormone, or aesthetics clinic already serving an aging demographic.
The treatment menu spans several well-established modalities, each with documented clinical use and a distinct patient population. No single-treatment model required.
Platelet-rich plasma drawn from the patient's own blood and injected into the scalp to support follicle health and regrowth. Autologous, prepared and returned in a single visit, and the most clinically documented regenerative hair treatment. The anchor service and the premium price point.
FDA-cleared LLLT devices for scalp stimulation and follicle activation. Works as a standalone or adjunct protocol, and generates recurring revenue from both in-clinic sessions and at-home device sales.
Minoxidil and finasteride remain the only FDA-approved treatments for androgenetic alopecia. Prescriber-directed, inexpensive to stock, and the most defensible foundation a hair clinic can build a menu on. Nearly every patient stays on one long term.
Scalp microneedling combined with topical protocols for follicle stimulation. Lower barrier to entry, consistent demand, and strong add-on revenue per visit. PRP and microneedling combinations are handled within the PRP protocol above.
GHK-Cu (copper peptide) applied topically for scalp health, within the limitations that apply to that route. Injectable peptide routes sit in a different regulatory position entirely, which is why route matters more than compound here. See our Peptide Therapy page for the full compound status table.
DHT-related hair loss ties directly to hormone balance. Clinics offering both hair regeneration and hormone optimization capture a significantly higher share of wallet per patient, and it is the most natural second category to add.
Hair regeneration clinics in the cash-pay space require a structured Medical Director relationship, and the scope of services determines the specific oversight model. PRP and regenerative treatments are medical procedures requiring physician oversight and state-specific compliance navigation.
This category has a clean path and a messy one. The clean path is autologous PRP, FDA-cleared laser devices, and FDA-approved topical and oral therapy. The messy path is cellular products and exosomes, where the FDA has approved nothing and enforcement is active. ACG builds clients on the first path.
ACG has already done the regulatory navigation. The supplier relationships, Medical Director introductions, and compliance framework are built into the engagement, not billed separately.
All regenerative hair treatments require physician oversight. ACG introduces clients to vetted Medical Directors with specific experience in this category across all 50 states.
ACG builds your treatment menu on well-established modalities and steers you away from products carrying active FDA enforcement risk, exosomes above all.
Who can perform scalp injections, what level of physician oversight is required, and how your entity structure affects liability, all mapped for your specific state.
A complete documentation framework: consent forms, treatment protocols, and patient intake structures built specifically for hair regeneration clinics.
Hair regeneration carries fewer paid advertising restrictions than peptide or hormone categories, a real acquisition advantage. Before-and-after imagery still has rules, and ACG supplies the compliant framing.
Hair loss is not a one-visit problem. Treatment protocols run 3 to 6 sessions minimum, and maintenance brings patients back quarterly or annually. A clinic that delivers visible results in this category builds a referral engine that compounds over time.
The demographic is also unusually broad. Hair loss affects men and women across every age group from late 20s through 70s. Few regenerative categories serve such a wide patient base with a single service menu.
3-6 Sessions
Per initial protocol, with quarterly or annual maintenance driving long-term recurring revenue.
$1,200-$3,500
Per treatment series. Premium PRP and restoration protocols command the higher end of this range.
Ages 28-70+
Male and female. One of the broadest demographics of any cash-pay health category.
Launch Window
From keys received, market and regulatory conditions permitting.
Operators looking at hair regeneration want straight answers on PRP compliance, treatment menu decisions, equipment economics, and where the patient volume actually comes from. Honest answers below.
If something isn't covered here, that's what the consultation is for. No pressure, no pitch.
View All FAQsHair restoration clinics rarely run a single offering. PRP and cellular or tissue-based service lines are commonly built into the same treatment room, and the operators with the widest compliant menu tend to hold patients longest.
The catch is that cellular and tissue-based products carry a regulatory burden that autologous PRP largely does not. Before you add that service line, you need to know precisely how your product is classified under 21 CFR Part 1271, and what your intended-use claims do to that classification.
A supplier calling a product 361 compliant is making a marketing claim, not a regulatory determination. Knowing the difference is the whole ballgame in this category.
Book a free 30-minute strategy call. ACG will walk you through the hair regeneration opportunity in your specific market, the demand data, the compliance picture, and what the launch process looks like from first call to open doors.
Book a Strategy CallFree 30-minute call · No pitch · ACG works with a select number of clients at any given time
Regenerative health is one of the most heavily scrutinized spaces in medicine. Knowing the rules is not a footnote to what we do. It is the foundation. Here is how we structure every clinic we help launch.
You own and operate the business. Every clinical, prescribing, and treatment decision is made by an independent, state-licensed Medical Director, structured to respect Corporate Practice of Medicine laws in your state. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications, and cellular products each carry their own federal and state rules, and not every product or use is FDA-approved. Some, like exosomes for therapeutic use, are not FDA-approved at all, and we steer you away from them. We help you build a treatment menu on defensible, compliant options and a marketing approach that holds up to FDA, FTC, and state medical board scrutiny.
We show you real ranges, not fantasy numbers, and we never promise an income or a clinical outcome. What you earn depends on your market, your capital, and your execution. We would rather set honest expectations than sell you a dream.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe, or sell any drug, biologic, device, or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the regulatory compliance of every product, therapy, and claim. See our full regulatory notice below.